# Rates of Major Depressive Disorder and Clinical Outcomes Following Traumatic Brain Injury

Charles H. Bombardier, PhD	
Jesse R. Fann, MD, MPH	
Nancy R. Temkin, PhD	
Peter C. Esselman, MD	
Jason Barber, MS	
Sureyya S. Dikmen, PhD	

RAUMATIC BRAIN INJURY (TBI) IS a major cause of disability in the United States1 and a signature injury among wounded soldiers.<sup>2</sup> Assessment and treatment of TBI typically focus on physical and cognitive impairments, yet psychological impairments represent significant causes of disability.3 Major depressive disorder (MDD) may be the most common and disabling psychiatric condition in individuals with TBI.4 Poorer cognitive functioning,<sup>5</sup> aggression and anxiety,6,7 greater functional disability,<sup>6,8</sup> poorer recovery,<sup>9</sup> higher rates of suicide attempts,<sup>10</sup> and greater health care costs<sup>11</sup> are thought to be associated with MDD after TBI.

Despite considerable research, the rates, predictors, and outcomes of MDD after TBI remain uncertain. Depression prevalence rates have ranged from 10% to 77%.12 Small sample size, selection bias, retrospective reporting, use of measures without diagnostic validity, and failure to exclude patients who were depressed at the time of injury have limited studies of rates and correlates of TBI-related MDD.13 More definitive studies could galvanize efforts to improve recognition and treatment of this important secondary condition. Therefore, we sought to describe the rate of MDD during the first year after TBI, multivariate predictors of MDD, MDD-related comorbidities, and

**Context** Uncertainties exist about the rates, predictors, and outcomes of major depressive disorder (MDD) among individuals with traumatic brain injury (TBI).

**Objective** To describe MDD-related rates, predictors, outcomes, and treatment during the first year after TBI.

**Design** Cohort from June 2001 through March 2005 followed up by structured telephone interviews at months 1 through 6, 8, 10, and 12 (data collection ending February 2006).

Setting Harborview Medical Center, a level I trauma center in Seattle, Washington.

**Participants** Five hundred fifty-nine consecutively hospitalized adults with complicated mild to severe TBI.

**Main Outcome Measures** The Patient Health Questionnaire (PHQ) depression and anxiety modules were administered at each assessment and the European Quality of Life measure was given at 12 months.

**Results** Two hundred ninety-seven of 559 patients (53.1%) met criteria for MDD at least once in the follow-up period. Point prevalences ranged between 31% at 1 month and 21% at 6 months. In a multivariate model, risk of MDD after TBI was associated with MDD at the time of injury (risk ratio [RR], 1.62; 95% confidence interval [CI], 1.37-1.91), history of MDD prior to injury (but not at the time of injury) (RR, 1.54; 95% CI, 1.31-1.82), age (RR, 0.61; 95% CI, 0.44-0.83 for  $\geq$ 60 years vs 18-29 years), and lifetime alcohol dependence (RR, 1.34; 95% CI, 1.14-1.57). Those with MDD were more likely to report comorbid anxiety disorders after TBI than those without MDD (60% vs 7%; RR, 8.77; 95% CI, 5.56-13.83). Only 44% of those with MDD received antidepressants or counseling. After adjusting for predictors of MDD, persons with MDD reported lower quality of life at 1 year compared with the nondepressed group.

**Conclusions** Among a cohort of patients hospitalized for TBI, 53.1% met criteria for MDD during the first year after TBI. Major depressive disorder was associated with history of MDD and was an independent predictor of poorer health-related quality of life. *JAMA. 2010;303(19):1938-1945* www.jama.com

the relationship of MDD to 1-year quality-of-life outcomes in a large prospectively studied sample of consecutive patients hospitalized for complicated mild to severe TBI.

## **METHODS**

This study was the recruitment phase of a clinical trial investigating the efficacy of sertraline for MDD after TBI. The trial is completed and the outcome analysis is in progress. Eligibility criteria for the cohort study were admission to Harborview Medical Center (a level I trauma center in Seattle, Washington) with TBI and radiological evidence of acute, traumatically induced brain abnormality or Glasgow Coma Scale (GCS) score lower than 13 (based on the lowest score within 24 hours after admission or the first af-

Author Affiliations: Departments of Rehabilitation Medicine (Drs Bombardier, Fann, Temkin, Esselman, and Dikmen), Psychiatry and Behavioral Sciences (Drs Fann and Dikmen), and Neurological Surgery (Drs Temkin and Dikmen and Mr Barber), University of Washington School of Medicine, Seattle; and Departments of Epidemiology (Dr Fann) and Biostatistics (Dr Temkin), University of Washington School of Public Health, Seattle.

**Corresponding Author:** Charles H. Bombardier, PhD, Department of Rehabilitation Medicine, Box 359612, Harborview Medical Center, 325 Ninth Ave, Seattle, WA 98104 (chb@uw.edu).


**1938** JAMA, May 19, 2010—Vol 303, No. 19 (Reprinted)

ter paralytic agents were withdrawn). Participants were residents of King. Pierce, Kitsap, Jefferson, Mason, Thurston, or Snohomish counties; at least 18 years old; and English speaking. We excluded those with uncomplicated mild TBI (GCS 13-15 and no radiological abnormality) because of diagnostic unreliability in this population.<sup>14</sup> Other exclusion criteria were homelessness, no contact information, incarceration, and schizophrenia (FIGURE 1). Participants with GCS scores lower than 13 and no radiological evidence of TBI were excluded if their blood alcohol levels exceeded 199 mg/dL because alcohol intoxication can decrease GCS scores.15 Enrollment occurred from June 2001 through March 2005 and follow-up assessments ended in February 2006. We obtained a waiver of consent to determine eligibility and retain selected demographic information about nonrecruited patients. Otherwise, participation required written consent. Study procedures were approved by the University of Washington institutional review board and followed guidelines from the Health Insurance Portability and Accountability Act.

#### Procedures

Consecutively eligible inpatients with TBI were identified via daily automatic queries of electronic medical records and TBI consultation lists. Research staff obtained consent from eligible patients who were fully oriented prior to discharge. For patients disoriented at discharge, we obtained assent from legal next of kin to conduct follow-up. We recruited patients not approached by discharge via a letter from the attending neurosurgeon and telephone calls. Trained research personnel used structured telephone interviews to assess participants monthly from months 1 through 6 and at 8, 10, and 12 months following injury. Patients were required to pass a standardized orientation examination<sup>16</sup> prior to consenting. We followed up disoriented patients for up to 1 year to determine whether they had become oriented and could be assessed.





(Reprinted) JAMA, May 19, 2010-Vol 303, No. 19 1939

#### Measures

Demographic, medical, radiologic, and International Classification of Diseases, Ninth Revision (ICD-9), code data were obtained via participant interviews, medical record reviews, and the Harborview Trauma Registry. Race was obtained via self-report and record review because depression prevalence may vary by race. Other system injury severity was based on the Injury Severity Score excluding head injury.<sup>17</sup> Serum blood alcohol level and toxicology screening results (cocaine and amphetamine) were available for 80% of the sample.

At the initial assessment, we conducted a structured interview to assess preinjury history of psychiatric disorders and treatment. Participants were coded as depressed at injury if they reported any of the following within 6 months prior to TBI: diagnosis of depression, depression-related antidepressant use, depression-related counseling, or a suicide attempt. Preinjury history of depression was defined as ever receiving a diagnosis of or treatment for depression or making a suicide attempt. Lifetime history of other mental health diagnoses was based on whether participants indicated they had ever been diagnosed with bipolar disorder or manic depression, generalized anxiety disorder, panic disorder, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, any phobia, schizophrenia, schizoaffective disorder, or any psychotic disorder. For descriptive purposes, we segregated lifetime history of depression or PTSD and collapsed the remainder of the diagnoses into "other mental health diagnoses." Lifetime alcohol dependence was based on endorsing at least 2 items on the CAGE (cut down, annoyed, guilty, eye opener-a screening questionnaire for potential alcoholism).18 Alcohol or drug abuse was defined as blood alcohol level greater than 79 mg/dL or positive toxicology screen for cocaine or amphetamine, respectively, on admission. Participants were asked whether they were involved in or planning a lawsuit related to their injury.

Longitudinal interviews focused on assessment of MDD as well as panic and

other anxiety disorders and treatment. Cases with MDD were identified using a structured interview based on the Patient Health Questionnaire 9-item depression scale (PHQ-9).<sup>19</sup> A telephoneadministered PHQ-9 has excellent interrater reliability (r=0.99) and good diagnostic sensitivity (0.93) and specificity  $(0.89)^{20}$  in individuals with TBI compared with the Structured Diagnostic Interview for DSM-IV (SCID).21 Participants were positive for MDD if they endorsed either depressed mood or anhedonia and a total of 5 or more symptoms of MDD at least several days during the prior 2-week period. Current panic disorder and other anxiety disorder were assessed on the same schedule using validated screening modules from the PHQ.<sup>22</sup> At each contact, participants were asked about receiving antidepressants or counseling for depression. Patients were referred for further evaluation and treatment if they reported suicidal ideation with plan or intent.

Outcomes assessed at 12 months included health-related quality of life (1item General Health Scale from the 36-Item Short Form Health Survey),<sup>23</sup> the European Quality of Life measure population-based weighted summary score,<sup>24</sup> and 5 subcomponents of the European Quality of Life measure. We measured social role impairment attributed to depression symptoms as described by Kroenke and colleagues<sup>19</sup> as well as current employment status and subjective percentage back to normal (preinjury functioning).<sup>25</sup>

#### **Data Analysis**

Postinjury MDD rates are estimated as the proportion of cases ascertained with MDD for the first time after TBI at each assessment among the total sample of 559 patients. Point prevalence is the proportion of participants positive for MDD, regardless of whether it was new, persisting, or recurrent, among those interviewed at that assessment. Participants were classified as MDD+ if they qualified as depressed at any screening call and MDD– if they never qualified. Likewise, a person was considered to have a comorbid condition or treatment if he or she

qualified at any interview. Both underestimate the true rates because participants may have had a condition only when they missed an interview. Binomial regression with a log-linear link (Proc GENMOD, SAS version 9.2; SAS Institute, Cary, North Carolina) was used for comparing the risk of MDD and relating MDD to binary outcomes with or without adjustment for other factors. To assess independent predictors of MDD, a backward stepwise procedure was used starting with a model containing all predictors in TABLE 1. Separate multivariate models were built for all participants and for those who were not depressed at injury. The bivariate relationship between MDD and continuous outcomes was assessed with t tests. We adjusted for full-sample predictors of MDD, using linear or log-binomial regression, to see whether MDD independently predicted outcomes. Months depressed was calculated as the number of positive monthly screens plus twice the number of positive bimonthly screens. All probabilities are 2-tailed. Nominal P values are presented, but the Bonferroni-corrected significance level is given in footnotes.

## RESULTS

We identified 1080 eligible patients, 559 of whom consented and underwent at least 1 interview. Those interviewed were significantly younger (mean [SD] age, 42.5 [17.9] vs 46.8 [21.5] years), more likely to have completed high school (89% vs 84%), and less likely to have Medicare insurance (16% vs 25%) compared with the nonrecruited group. The 2 groups were equivalent in terms of sex ratio, race, marital status, cause of injury, coma severity, other system injury severity, blood alcohol level, toxicology findings, and length of hospital stay. Participant interview rates among those eligible for interview at the 9 assessment points ranged from 79% to 90% (Figure 1). Fewer participants were interviewed at month 1 (n=289) vs subsequent months (n=358-432), primarily because more participants at month 1 were not eligible for interview, eg, pending consent (n=182) or not yet oriented (n=30).

1940 JAMA, May 19, 2010-Vol 303, No. 19 (Reprinted)

#### **Rates of MDD**

During the first year after TBI, 297 of 559 patients (53.1%) met criteria for MDD at least once (FIGURE 2). The point prevalence of MDD was highest the first month after TBI. Point prevalence ranged from 21% to 31% with no trend (eFigure 1, available at http: //www.jama.com). Among those screening positive for MDD in the first 3 months and interviewed at least twice, the median time depressed was 4 months; 27% screened positive only once, and 36% screened positive for 6 or more months (eFigure 2). Excluding those depressed at the time of injury, the rate of new (incident) MDD was 49% (233/471).

#### **Predictors of MDD**

Table 1 shows the composition of the 559 participants interviewed as well as the percentage depressed during the study period in various subgroups based on demographics and injury characteristics and the univariate risk ratio (RR) for depression. Participants were mostly men injured in vehicular crashes who sustained complicated mild injuries. Factors closely related to MDD when considered individually include age; sex; cocaine intoxication; lifetime alcohol dependence; and preinjury history of depression, PTSD, or other mental health diagnosis. Independent predictors of MDD in the multivariate models (TABLE 2) were age and preinjury depression for both the full sample and the sample that excluded those depressed at injury. Lifetime alcohol dependence was independently associated with MDD only in the full sample model, and sex was associated with MDD only in the sample not depressed at injury. FIGURE 3 and eFigures 3 through 5 display the cumulative rate of MDD depending on history of depression, PTSD, alcohol dependence, and other mental health diagnosis. The group with preinjury history of depression comprised those with a history of depression diagnosis (n=61, n=61)41%); a history of suicide attempt (n=41, 28%); or treatment for depression, including antidepressants (n=121,81%), inpatient treatment (n=17, 11%),

**Table 1.** Demographic and Injury Characteristics of Participants (N = 559) According to Depression Status<sup>a</sup>

	MDD-	MDD+	MDD,	Log-Binomial Regression		
Variable	(n = 262)	(n = 297)	% <sup>b</sup>	RR (95% CI)	P Value <sup>c</sup>	
Age, y 18-29	83	92	52.6	1 [Reference]	<.001	
30-44	46	103	69.1	1.31 (1.10-1.57)	.001	
45-59	64	71	52.6	1.00 (0.81-1.24)	>.99	
≥60	69	31	31.0	0.59 (0.43-0.82)	.001	
Sex			0.110		1001	
Male	205	195	48.8	1 [Reference]	.001	
Female	57	102	64.2	1.32 (1.13-1.53)	.001	
Race Non-Hispanic white	232	245	51.4	1 [Reference]	.25	
Hispanic or Latino	10	14	58.3	1.14 (0.80-1.61)	.23	
Non-Hispanic African American	10	19	65.5	1.28 (0.97-1.68)	.40	
Asian/Pacific Islander	7	10	58.8	1.15 (0.76-1.72)	.51	
Other	3	9	75.0	1.46 (1.04-2.05)	.03	
Education						
<high school<="" td=""><td>19</td><td>39</td><td>67.2</td><td>1 [Reference]</td><td>.01</td></high>	19	39	67.2	1 [Reference]	.01	
High school or more	241	258	51.7	0.77 (0.63-0.94)	.01	
Marital status	00	100	50.0	1 [Defeuence]	15	
Never married Married	99	130 103	56.8 47.9	1 [Reference] 0.84 (0.71-1.01)	.15 .06	
Divorced/separated/widowed	51	64	55.7	0.98 (0.80-1.20)	.00	
Insurance	51	04	55.7	0.90 (0.00-1.20)	.00	
Commercial or private	155	161	50.9	1 [Reference]	.01	
Medicaid	54	99	64.7	1.27 (1.08-1.49)	.003	
Medicare	53	37	41.1	0.81 (0.62-1.06)	.12	
Cause of injury						
Fall	97	87	47.3	1 [Reference]	.01	
Vehicular	113	149	56.9	1.20 (1.00-1.45)	.05	
Violence	22	41	65.1	1.38 (1.09-1.74)	.008	
Other/recreational	30	20	40.0	0.85 (0.58-1.23)	.38	
Glasgow Coma Scale score Complicated mild (13-15)	140	151	51.9	1 [Reference]	.55	
Moderate (9-12)	62	66	51.6	0.99 (0.81-1.22)	.95	
Severe (3-8)	60	80	57.1	1.10 (0.92-1.32)	.30	
Cortical contusions						
No	179	216	54.7	1 [Reference]	.30	
Yes	81	80	49.7	0.91 (0.76-1.09)	.30	
Intracerebral hemorrhage No	79	95	54.6	1 [Reference]	.66	
Yes	181	201	52.6	0.96 (0.82-1.14)	.66	
Injury score, excluding head						
	75	78	51.0	1 [Reference]	.38	
1-2	94	98	51.0	1.00 (0.81-1.23)	.99	
3-5	91	121	57.1	1.12 (0.92-1.36)	.26	
Length of hospital stay, d	01	07	51.0	1 [Deferrence]	00	
<u>0-3</u> <u>4-7</u>	81 56	87 66	51.8 54.1	1 [Reference] 1.05 (0.84-1.30)	.98	
8-14	60	70	53.8	1.04 (0.84-1.29)	.70 .72	
<u>0-14</u> ≥15	63	70	53.7	1.04 (0.84-1.29)	.72	
Cocaine intoxication	50	10	00.1	1.0- (0.0- 1.20)	.14	
No	199	207	51.0	1 [Reference]	<.001	
Yes	7	34	82.9	1.63 (1.37-1.93)	<.001	
Methamphetamine intoxication	107	010	50 F	1 [Deference]	000	
No	197	218	52.5	1 [Reference]	.009	
Yes	9	23	71.9	1.37 (1.08-1.73)	.009	

©2010 American Medical Association. All rights reserved.

(Reprinted) JAMA, May 19, 2010—Vol 303, No. 19 1941

or outpatient counseling (n=52, 35%). Patients with TBI with or without these comorbid conditions appeared to be at risk of MDD throughout the 12 months.

#### **Comorbid Anxiety**

Major depressive disorder was associated with increased risk of meeting criteria for post-TBI panic disorder (27%

<b>Table 1.</b> Demographic and Injury Characteristics of Participants (N = 559) According to	
Depression Status <sup>a</sup> (continued)	


	MDD- (n = 262)	MDD+ (n = 297)	MDD, % <sup>b</sup>	Log-Binomial Regression	
Variable				RR (95% CI)	P Value <sup>c</sup>
Alcohol level, mg/dL					
0	136	166	55.0	1 [Reference]	.25
1-79	22	15	40.5	0.74 (0.49-1.10)	.14
>79	104	116	52.7	0.96 (0.82-1.13)	.61
Depression history					
No history of depression	191	130	40.5	1 [Reference]	<.001
Preinjury history of depression, not at injury	47	103	68.7	1.70 (1.43-2.01)	<.001
Depressed at injury	24	64	72.7	1.80 (1.49-2.16)	<.001
PTSD history					
No	251	256	50.5	1 [Reference]	<.001
Yes	7	29	80.6	1.60 (1.33-1.91)	<.001
Other mental health diagnosis history <sup>d</sup>					
No	250	241	49.1	1 [Reference]	<.001
Yes	9	52	85.2	1.74 (1.51-1.99)	<.001
Lifetime alcohol dependence					
CAGE score 0-1	153	125	45.0	1 [Reference]	<.001
CAGE score ≥2	58	133	69.6	1.55 (1.32-1.82)	<.001
Litigation related to TBI					
No	166	181	52.2	1 [Reference]	.02
Yes	29	55	65.5	1.26 (1.04-1.51)	.02


Abbreviations: CAGE, cut down, annoyed, guilty, eye opener—a screening questionnaire for potential alcoholism; Cl, confidence interval; MDD-/+, negative or positive for major depressive disorder; PTSD, posttraumatic stress disorder; RR, risk ratio; TBI, traumatic brain injury. <sup>a</sup>Patients were counted in the MDD+ group if they met the criteria at any interview (53.1% of 559 participants).

<sup>a</sup>Patients were counted in the MDD+ group if they met the criteria at any interview (53.1% of 559 participants). <sup>b</sup>Percentage with MDD within each variable category.

<sup>C</sup> All results in this table are from univariate analyses. The P value in the row for the reference level reflects an overall difference among the levels of the variable. The P value for each nonreference level refers to the RR comparing that level with the reference level. P values ≤.001 are significant after adjusting for the 45 comparisons within the table using the Bon, ferron i correction.

<sup>d</sup> Other mental health diagnoses included bipolar disorder or manic depression, generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, any phobia, schizophrenia, schizoaffective disorder, or any psychotic disorder.





Postinjury rate is the proportion of cases ascertained with major depressive disorder for the first time after traumatic brain injury at each assessment. The values underestimate the true rates because not all participants were assessed at each time. Error bars indicate 95% confidence intervals.

**1942** JAMA, May 19, 2010—Vol 303, No. 19 (Reprinted)

vs 1%; RR=23.82; 95% confidence interval [CI], 7.62-74.50) and other anxiety disorder (54% vs 6%; RR=8.82; 95% CI, 5.42-14.35) (eTable 1). Those with MDD were more likely to report any comorbid anxiety disorders after TBI than those without MDD (60% vs 7%; RR, 8.77; 95% CI, 5.56-13.83).

#### **Mental Health Treatment**

Individuals with MDD were more likely to receive antidepressants (41% vs 18%; RR=2.26; 95% CI, 1.67-3.05) and counseling (20% vs 5%; RR=3.92; 95% CI, 2.20-7.00) during the year after TBI compared with those without MDD (excluding participants in the treatment trial) (eTable 1). Only 44% of those with MDD received antidepressants or counseling.

### Health-Related Quality of Life and Role Impairment at 12 Months

Major depressive disorder within the first year after TBI was associated with greater problems with mobility, usual activities, and pain/discomfort and greater difficulty with role functioning at 12 months after TBI, after controlling for MDD-related risk factors (eTable 2).

### COMMENT

The 1-year cumulative rate of MDD in this study sample is 7.9-times greater than would be expected in the general population (53.1% in our cohort vs 6.7% in the general population).<sup>26</sup> Previous high-quality studies may have underestimated the rates of MDD during the first year after TBI by reporting rates in the 12% to 42.3% range.7,27,28 Our rate estimate may be higher because we conducted frequent assessments and were able to capture the cases with transient (1-month) major depressive episodes. In addition, the sample was characterized by high rates of depression-related risk factors such as alcohol dependence and other preinjury mental health diagnoses. Nevertheless, because of incomplete data at each assessment time point, the rate and depression duration estimates are likely conservative.

Our data indicate that 15.7% of the sample were depressed at the time of injury and that 26.8% had a preinjury history of depression but were not depressed when injured. Of the total sample, 11.4% had a major depressive episode both at injury and after the injury, 18.4% experienced a recurrence of major depression after the injury, and 23.3% experienced MDD for the first time after the injury. Only 46.9% did not experience MDD in the year after injury. Preinjury depression and depression at the time of injury heralded higher post-TBI rates of MDD compared with those with no depression history. Nevertheless, by 12 months, 41% of those with no preinjury depression history also had an episode of MDD. High rates of preinjury depression in this and other samples<sup>7,29</sup> compared with the lifetime prevalence of MDD in the general population (16.2%)<sup>30</sup> is consistent with the notion that depression is a risk factor for TBI.<sup>29</sup> Our estimate of preinjury depression may be higher than other studies because we included prior antidepressant treatment, prior psychotherapy for depression, and history of suicide attempt as indicators of depression history.

Several features of MDD after TBI are pertinent to future detection and treatment efforts. About half of the patients who became depressed were identified by 3 months. These data contradict the theory that poor awareness of impairment precludes depressive reactions during the first 6 months after injury<sup>31</sup> and suggest a window of opportunity for early identification and treatment or prevention efforts. Nevertheless, TBI survivors remained at risk of MDD throughout the first year regardless of preinjury depression history. Risk of post-TBI MDD probably persists beyond 1 year since the curves (Figure 3, eFigures 3 through 5) do not seem to level off by 12 months. In 27% of cases, MDD lasted only 1 month and may not have required treatment. Depression after TBI was complicated by a history of substance abuse disorders and PTSD as well as co-occurring anxiety, conditions that can limit the efficacy of antidepressants.32

Multivariate risk factors for MDD following TBI were similar to those for primary MDD in the general population.<sup>33</sup> History of depression around the time of injury and history of depression prior to that time were the strongest predictors of post-TBI depression. These data contradict theories that history of psychiatric disorder is either unrelated to<sup>28</sup> or inversely related to MDD following TBI.<sup>4</sup> The relationship of alcohol dependence to both TBI<sup>34,35</sup> and depression merits particular attention as a potentially modifiable risk factor. We did not find a relationship between injury characteristics and rate of MDD. Severity of TBI as a predictor of MDD has been controversial.<sup>13</sup> Other biological markers, such as the apolipoprotein E  $\varepsilon$ 4 allele, neurotransmit-

	Full Sam (n = 559		Newly Depressed Sample (n = 471) <sup>b</sup>		
Variable <sup>a</sup>	RR (95% CI)	P Value <sup>c</sup>	RR (95% CI)	P Value <sup>c</sup>	
Age, y 18-29	1 [Reference]	<.001	1 [Reference]	<.001	
30-44	1.15 (0.99-1.34)	.07	1.18 (0.98-1.43)	.07	
45-59	0.95 (0.79-1.15)	.63	0.82 (0.67-1.02)	.07	
≥60	0.61 (0.44-0.83)	.002	0.65 (0.48-0.88)	.005	
Sex Male			1 [Reference]	<.001	
Female			1.27 (1.07-1.52)	<.001	
Depression history No history of depression	1 [Reference]	<.001	1 [Reference]	<.001	
Preinjury history of depression, not at injury	1.54 (1.31-1.82)	<.001	1.44 (1.23-1.68)	<.001	
Depressed at injury	1.62 (1.37-1.91)	<.001			
Lifetime alcohol dependence CAGE score 0-1	1 [Reference]	<.001			
CAGE score ≥2	1.34 (1.14-1.57)	<.001			


Abbreviations: CAGE, cut down, annoyed, guilty, eye opener—a screening questionnaire for potential alcoholism; Cl, confidence interval; RR, risk ratio.

<sup>a</sup> These models are the result of stepwise regression starting with all the variables in Table 1; nonsignificant variables have been removed, leaving the independent predictors shown in the table.

<sup>b</sup> The newly depressed sample consists only of those patients who were not depressed at the time of injury. <sup>c</sup> The *P* value in the row for the reference level reflects an overall difference among the levels of the variable. The *P* value for each nonreference level refers to the RR comparing that level with the reference level. *P* values ≤.003 are significant after

each nonreference level refers to the RR comparing that level with the reference level. P values  $\leq$  .003 are significant after adjusting for the 14 comparisons within the table using the Bonferroni correction.

**Figure 3.** Cumulative Rate of Major Depression After Traumatic Brain Injury as a Function of Depression History (N=559)



There were significant differences in depression rates between groups as shown in Table 1. Error bars indicate 95% confidence intervals.

<sup>(</sup>Reprinted) JAMA, May 19, 2010-Vol 303, No. 19 1943

ter and neuroendocrine changes, genetic polymorphisms, and psychosocial risk factors, merit further study.<sup>35</sup>

Depression after TBI was associated with comorbid anxiety and poorer functional outcomes in multiple domains 1 year after injury. After we controlled for all variables associated with depression after TBI, MDD remained a significant predictor of poorer self-reported health and lower quality of life. These results are correlational; therefore, causality cannot be inferred. Prior research has linked post-TBI depression with a host of poorer subjective and objective outcomes.<sup>5-7</sup> Effective depression treatment may reduce disability,<sup>36</sup> and this hypothesis deserves further research.

Depression was undertreated in the study sample. Moreover, based on research in primary care settings, we suspect that an even smaller proportion received guideline-level depression treatment.<sup>37</sup> The dearth of rigorous pharmacotherapy and psychotherapy trials likely contributes to the inadequate treatment of MDD after TBI. Only 1 negative but underpowered class I antidepressant (sertraline) treatment trial has been published.<sup>38</sup> A randomized placebocontrolled depression prevention trial found that 50 mg of sertraline daily for 3 months after TBI resulted in significantly lower depression severity in the treated group vs controls at the end of the trial but not beyond.39

Psychotherapy was especially underused in our sample, possibly due to poor access to counseling. A trial of proactive telephone counseling has demonstrated that patients receiving treatment reported less depressive symptomatology 1 year after TBI compared with controls receiving usual care.<sup>40</sup> Additionally, survey research indicates that individuals with TBI favor counseling and physical exercise over other depression treatment modalities.<sup>41</sup> In-person or telephone counseling was preferred over Internet-delivered depression treatment.

Characteristics and comorbidities of TBI-related depression may influence treatment efficacy.<sup>35</sup> For example, executive dysfunction, which is common following TBI, predicts poor response to selective serotonin reuptake inhibitors in non-TBI samples.<sup>42</sup> Cognitive impairments may affect the feasibility and efficacy of standard psychotherapeutic interventions. Integrated medical and psychosocial interventions, including substance abuse interventions, might be required to produce satisfactory outcomes.

Systematic integration of mental health services into standard care of patients with TBI may be needed to improve longterm outcomes after TBI. Within inpatient rehabilitation, integrated clinical pathways can be used to organize early identification, risk assessment, diagnosis, and guideline-driven treatment of MDD.43 Systematic depression screening and stepped-care treatment protocols should be integrated into routine outpatient care. For those without or beyond routine follow-up, novel casefinding programs may be useful, possibly via scheduled telephone contacts,44 Internet-based screening<sup>45</sup> or other technology-assisted methods.46 The manner in which substance abuse treatment has been integrated into trauma care47 and depression treatment integrated into primary care48 may provide models of how to incorporate depression treatment into TBI care.

Several study limitations should be highlighted. First, the presence or absence of MDD was based on structured telephone interviews using the PHQ-9, not more traditional diagnostic interviews such as the SCID. Nevertheless, we have reported excellent interrater reliability and good diagnostic sensitivity and specificity when comparing the PHQ-9 with the SCID in individuals with TBI.<sup>20</sup> Caution should be exercised comparing these results with studies that have used other diagnostic approaches.

Next, the study was conducted at a single level I trauma center serving the northwestern United States. The patient population was characterized by high rates of Medicaid recipients and somewhat limited ethnic/racial diversity. The results of this study may not be generalizable to other regions or populations with different socioeconomic or ethnic/racial characteristics. The recruitment rate for this study was 52%. While this rate seems low, other widely referenced prevalence studies were based on convenience or referral samples or did not report recruitment rates and did not assess selection bias.<sup>13</sup> Trauma patients, especially persons with TBI, are difficult to recruit and follow up,<sup>49</sup> resulting in unrepresentative samples. Our study sample was comparable with the nonrecruited group on most dimensions, although they were younger, more likely to have completed high school, and less likely to have Medicare insurance.

We found no differences in rates of MDD among those with complicated mild, moderate, or severe TBI. However, caution is advised extrapolating these results to persons with uncomplicated mild TBI, who constitute the majority of those who sustain TBI.<sup>1</sup> Although a significant number of such patients seek medical attention, adequate information about rates of complicated recoveries is lacking and deserves future research.

In conclusion, MDD after TBI is highly prevalent and associated with increased comorbidity and disability. Because MDD after TBI is an invisible disorder within an often invisible injury, aggressive efforts are needed to educate clinicians about the importance of MDD in this population, to promote integrated systems of detection and multidisciplinary care, and to conduct intervention studies aimed at overcoming multiple barriers to effective treatment.

Study concept and design: Bombardier, Fann, Temkin, Esselman. Dikmen.

Acquisition of data: Bombardier, Fann, Temkin.

Analysis and interpretation of data: Bombardier, Fann,

Temkin, Barber. Drafting of the manuscript: Bombardier, Fann, Temkin,

Barber.

Critical revision of the manuscript for important intellectual content: Fann, Temkin, Esselman, Dikmen. Statistical analysis: Temkin, Barber.

*Obtained funding:* Bombardier, Fann, Temkin, Dikmen. *Administrative, technical, or material support:* Fann, Esselman.

Study supervision: Bombardier, Fann.

Financial Disclosures: Dr Bombardier reported ownership of Pfizer stock. Dr Fann reported ownership of Pfizer and Amgen stock. Dr Temkin reported ownership of stock in Amgen and Kimberly-Clark and consultancies

**1944** JAMA, May 19, 2010—Vol 303, No. 19 (Reprinted)

Author Contributions: Dr Bombardier had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

with or honoraria from Novartis, Celgene, Eisai, Pfizer, Par Pharmaceutical Companies, UCB, Actelion, and GlaxoSmithKline. Dr Esselman reported ownership of Eli Lilly stock. No other disclosures were reported.

Funding/Support: This work was supported by the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health grant R01 HD39415 to Drs Bombardier and Fann (co-principal investigators). Pfizer supplied masked sertraline and placebo for the controlled trial.

Role of the Sponsor: The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Medical Rehabilitation Research.

Previous Presentations: Parts of the manuscript were presented at the annual national meetings of the American Psychological Association, Rehabilitation Psychology Division; Charlotte, North Carolina; March 2007; and the Academy of Psychosomatic Medicine; Amelia Island, Florida; November 2007.

**Online-Only Material:** eFigures 1 through 5 and eTables 1 and 2 are available at http://www.jama .com.

Additional Contributions: Erika Pelzer, BS, University of Washington School of Medicine, provided expert assistance and oversight in data collection efforts. She was compensated for her contributions.

#### REFERENCES

1. Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil. 2006;21(5): 375-378.

2. Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in US soldiers returning from Iraq. *N Engl J Med*. 2008; 358(5):453-463.

 NIH Consensus Development Panel on Rehabilitation of Persons With Traumatic Brain Injury. Rehabilitation of persons with traumatic brain injury. JAMA. 1999;282(10):974-983.

 Hibbard MR, Uysal S, Kepler K, Bogdany J, Silver J. Axis I psychopathology in individuals with traumatic brain injury. J Head Trauma Rehabil. 1998; 13(4):24-39.

5. Chamelian L, Feinstein A. The effect of major depression on subjective and objective cognitive deficits in mild to moderate traumatic brain injury. *J Neuropsychiatry Clin Neurosci.* 2006;18(1):33-38.

**6.** Fann JR, Katon WJ, Uomoto JM, Esselman PC. Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. *Am J Psychiatry*. 1995;152(10):1493-1499.

**7.** Jorge RE, Robinson RG, Moser D, Tateno A, Crespo-Facorro B, Arndt S. Major depression following traumatic brain injury. *Arch Gen Psychiatry*. 2004; 61(1):42-50.

 Hibbard MR, Ashman TA, Spielman LA, Chun D, Charatz HJ, Melvin S. Relationship between depression and psychosocial functioning after traumatic brain injury. Arch Phys Med Rehabil. 2004;85(4)(suppl 2): S43-S53.

**9.** Mooney G, Speed J, Sheppard S. Factors related to recovery after mild traumatic brain injury. *Brain Inj.* 2005;19(12):975-987.

**10.** Silver JM, Kramer R, Greenwald S, Weissman M. The association between head injuries and psychiatric disorders: findings from the New Haven NIMH Epidemiologic Catchment Area Study. *Brain Inj*. 2001; 15(11):935-945.

**11.** Dobrez D, Heinemann AW, Deutsch A, Durkin EM, Almagor O. Impact of mental disorders on cost and reimbursement for patients in inpatient rehabili-

tation facilities. Arch Phys Med Rehabil. 2010; 91(2):184-188.

**12.** Rosenthal M, Christensen BK, Ross TP. Depression following traumatic brain injury. *Arch Phys Med Rehabil*. 1998;79(1):90-103.

**13.** van Reekum R, Cohen T, Wong J. Can traumatic brain injury cause psychiatric disorders? *J Neuropsychiatry Clin Neurosci.* 2000;12(3):316-327.

**14.** Esselman PC, Uomoto JM. Classification of the spectrum of mild traumatic brain injury. *Brain Inj.* 1995; 9(4):417-424.

**15.** Jagger J, Fife D, Vernberg K, Jane JA. Effect of alcohol intoxication on the diagnosis and apparent severity of brain injury. *Neurosurgery*. 1984;15(3): 303-306.

**16.** Kiernan RJ, Mueller J, Langston JW, Van Dyke C. The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. *Ann Intern Med.* 1987;107(4):481-485.

**17.** Baker SP, O'Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. *J Trauma*. 1974;14(3):187-196.

**18.** Fiellin DA, Reid MC, O'Connor PG. Screening for alcohol problems in primary care: a systematic review. *Arch Intern Med.* 2000;160(13):1977-1989.

**19.** Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 2001;16(9):606-613.

**20.** Fann JR, Bombardier CH, Dikmen S, et al. Validity of the Patient Health Questionnaire-9 in assessing depression following traumatic brain injury. *J Head Trauma Rehabil*. 2005;20(6):501-511.

**21.** First MB, Gibbon M, Spitzer RL, Williams JB. User's Guide for the Structured Clinical Interview for DSM-IV-TR Axis I Disorders—Research Version. New York, NY: Biometrics Research Dept, New York State Psychiatric Institute; 2001.

22. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study: Primary Care Evaluation of Mental Disorders: Patient Health Questionnaire. *JAMA*. 1999;282(18):1737-1744.

**23.** Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I, Conceptual framework and item selection. *Med Care*. 1992;30(6): 473-483.

24. Calculating the US population-based EQ-5D index score. Agency for Healthcare Research and Quality. http://www.ahrq.gov/rice/EQ5Dscore.htm. Accessed April 14, 2010.

25. Powell JM, Machamer JE, Temkin NR, Dikmen SS. Self-report of extent of recovery and barriers to recovery after traumatic brain injury: a longitudinal study. *Arch Phys Med Rehabil*. 2001;82(8):1025-1030.

26. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month *DSM-IV* disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005; 62(6):617-627.

27. Fann JR, Burington B, Leonetti A, Jaffe K, Katon WJ, Thompson RS. Psychiatric illness following traumatic brain injury in an adult health maintenance organization population. *Arch Gen Psychiatry*. 2004; 61(1):53-61.

**28.** Jorge RE, Robinson RG, Arndt SV, Starkstein SE, Forrester AW, Geisler F. Depression following traumatic brain injury: a 1 year longitudinal study. *J Affect Disord*. 1993;27(4):233-243.

**29.** Fann JR, Leonetti A, Jaffe K, Katon WJ, Cummings P, Thompson RS. Psychiatric illness and subsequent traumatic brain injury: a case control study. *J Neurol Neurosurg Psychiatry*. 2002;72(5):615-620.

**30.** Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA*. 2003;289(23):3095-3105. **31.** Moldover JE, Goldberg KB, Prout MF. Depression after traumatic brain injury: a review of evidence for clinical heterogeneity. *Neuropsychol Rev.* 2004; 14(3):143-154.

**32.** Rush AJ, Warden D, Wisniewski SR, et al. STAR\*D: revising conventional wisdom. *CNS Drugs*. 2009; 23(8):627-647.

**33.** Fava M, Kendler KS. Major depressive disorder. *Neuron*. 2000;28(2):335-341.

**34.** Bombardier CH, Rimmele CT, Zintel H. The magnitude and correlates of alcohol and drug use before traumatic brain injury. *Arch Phys Med Rehabil*. 2002; 83(12):1765-1773.

**35.** Jorge RE, Starkstein SE. Pathophysiologic aspects of major depression following traumatic brain injury. *J Head Trauma Rehabil*. 2005;20(6):475-487.

**36.** Fann JR, Uomoto JM, Katon WJ. Cognitive improvement with treatment of depression following mild traumatic brain injury. *Psychosomatics*. 2001;42 (1):48-54.

37. Simon GE, Von Korff M, Rutter CM, Peterson DA. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry. 2001;58(4):395-401.

**38.** Ashman TA, Cantor JB, Gordon WA, et al. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury. *Arch Phys Med Rehabil*. 2009;90(5):733-740.

**39.** Novack TA, Banos JH, Brunner R, Renfroe S, Meythaler JM. Impact of early administration of sertraline on depressive symptoms in the first year after traumatic brain injury. *J Neurotrauma*. 2009;26 (11):1921-1928.

**40.** Bombardier CH, Bell KR, Temkin NR, Fann JR, Hoffman J, Dikmen S. The efficacy of a scheduled telephone intervention for ameliorating depressive symptoms during the first year after traumatic brain injury. *J Head Trauma Rehabil*. 2009;24(4):230-238.

**41.** Fann JR, Jones AL, Dikmen SS, Temkin NR, Esselman PC, Bombardier CH. Depression treatment preferences after traumatic brain injury. *J Head Trauma Rehabil*. 2009;24(4):272-278.

**42.** Gorlyn M, Keilp JG, Grunebaum MF, et al. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. *J Neural Transm.* 2008;115(8):1213-1219.

**43.** Turner-Stokes L, Hassan N, Pierce K, Clegg F. Managing depression in brain injury rehabilitation: the use of an integrated care pathway and preliminary report of response to sertraline. *Clin Rehabil.* 2002;16 (3):261-268.

**44.** Bell KR, Temkin NR, Esselman PC, et al. The effect of a scheduled telephone intervention on outcome after moderate to severe traumatic brain injury: a randomized trial. Arch Phys Med Rehabil. 2005;86 (5):851-856.

**45.** Donker T, van Straten A, Marks I, Cuijpers P. A brief Web-based screening questionnaire for common mental disorders: development and validation. *J Med Internet Res.* 2009;11(3):e19.

**46.** Huddleston M, Kobb R. Emerging technology for at-risk chronically ill veterans. *J Healthc Qual*. 2004; 26(6):12-15.

**47.** Gentilello LM, Donovan DM, Dunn CW, Rivara FP. Alcohol interventions in trauma centers: current practice and future directions. *JAMA*. 1995;274 (13):1043-1048.

**48.** Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ. Collaborative care for depression: a cumulative metaanalysis and review of longer-term outcomes. *Arch Intern Med.* 2006;166(21):2314-2321.

**49.** Corrigan JD, Bogner JA, Mysiw WJ, Clinchot D, Fugate L. Systematic bias in outcome studies of persons with traumatic brain injury. *Arch Phys Med Rehabil.* **1997**;78(2):132-137.